New York S 987: Prohibits and regulates the discovery and disclosure of immigration status; repealer

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S00987 Summary:

BILL NOS00987 

&nbsp

SAME ASSAME AS A02650

&nbsp

SPONSORBROUK

&nbsp

COSPNSRADDABBO

&nbsp

MLTSPNSR

&nbsp

Amd §273, Pub Health L; add §3216-a, Ins L

&nbsp

Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.

Go to top S00987 Actions:

BILL NOS00987 

&nbsp

01/08/2025REFERRED TO HEALTH

01/07/2026REFERRED TO HEALTH

Go to topS00987 Committee&nbspVotes:

Go to topS00987 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS00987 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 987

 2025-2026 Regular Sessions

 IN SENATE

 (Prefiled)

 January 8, 2025
 ___________

 Introduced by Sen. BROUK -- read twice and ordered printed, and when
 printed to be committed to the Committee on Health

 AN ACT to amend the public health law and the insurance law, in relation
 to the use of abuse-deterrent technology for opioids as a mechanism
 for reducing abuse and diversion of opioid drugs

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Section 273 of the public health law is amended by adding a
 2 new subdivision 11 to read as follows:
 3 11. Any prior authorization requirements for opioid analgesic and any
 4 service denials made pursuant thereto shall not require use of opioid
 5 analgesic drug products without abuse-deterrent properties before
 6 authorizing the use of abuse-deterrent opioid analgesic drug products.
 7 § 2. The insurance law is amended by adding a new section 3216-a to
 8 read as follows:
 9 § 3216-a. Access to abuse-deterrent opioid medications. (a) An insur-
 10 ance carrier or health plan shall provide coverage on its formulary,
 11 drug list or other lists of similar construct for at least one abuse-
 12 deterrent opioid analgesics drug product per opioid analgesics active
 13 ingredient.
 14 (1) Cost-sharing for brand name abuse-deterrent opioid analgesic drug
 15 products covered pursuant to this section shall not exceed the lowest
 16 cost-sharing level applied to brand name non-abuse deterrent opioid
 17 drugs covered under the applicable health plan or policy.
 18 (2) Cost-sharing for generic abuse-deterrent opioid analgesic drug
 19 products covered pursuant to this section shall not exceed the lowest
 20 cost-sharing level applied to generic non-abuse deterrent opioid drugs
 21 covered under the applicable health plan or policy.

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD01185-01-5

 S. 987 2

 1 (3) An increase in patient cost-sharing or disincentives for prescri-
 2 bers or dispensers shall not be allowed to achieve compliance with this
 3 section.
 4 (b) Any prior-authorization requirements or other utilization review
 5 measures for opioid analgesics, and any service denials made pursuant
 6 thereto, shall not require use of opioid analgesic drug products without
 7 abuse-deterrent properties in order to access abuse-deterrent opioid
 8 analgesic drug products.
 9 (c) Definitions. As used in this section:
 10 (1) "Opioid analgesic drug product" means a drug in the opioid anal-
 11 gesic drug class prescribed to treat moderate to severe pain or other
 12 conditions, whether in immediate release or extended long acting release
 13 form and whether or not combined with other drug substances to form a
 14 single drug product or other dosage form.
 15 (2) "Abuse deterrent opioid analgesic drug product" means a brand or
 16 generic opioid analgesic drug product approved by the federal food and
 17 drug administration with abuse-deterrence labeling claims indicating its
 18 abuse-deterrent properties are expected to deter or reduce its abuse.
 19 (3) "Cost-sharing" means any coverage limit, copayment, coinsurance,
 20 deductible or other out-of-pocket patient expense requirements.
 21 § 3. This act shall take effect on the one hundred twentieth day after
 22 it shall have become a law, and shall apply to all policies and
 23 contracts issued, renewed, modified, altered or amended on or after such
 24 date.

Go to top 

• 

 Sitemap 

 Request Information 

 Directions and Maps